Prof. Andrew Roberts
Metcalf Chair In Leukaemia Research
Centre for Cancer Research
281 Scholarly works
4 Projects
HIGHLIGHTS
2020
Journal article
Therapeutic development and current uses of BCL-2 inhibition
DOI: 10.1182/hematology.20200001542020
Journal article
Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia
DOI: 10.1182/blood-2020-1368722020
Journal article
The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
DOI: 10.1182/blood-2020-1417112020
Journal article
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
DOI: 10.1182/bloodadvances.20190014162020
Research Grant
Exploring the potential of BH3 mimetic anti-cancer drugs in blood cancers
2017
Research Grant
THE INTERNATIONAL ACUTE MYELOID LEUKAEMIA PLATFORM CONSORTIUM (IAPC)
2015
Research Grant
TRANSLATING ADVANCES IN MOLECULAR ONCOLOGY INTO IMPROVED CARE FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
RECENT SCHOLARLY WORKS
2020
Journal article
BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
DOI: 10.1182/blood-2020-1377752020
Journal article
Targeting MCL-1 in hematologic malignancies: Rationale and progress
DOI: 10.1016/j.blre.2020.1006722020
Journal article
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
DOI: 10.1182/blood.20200064492020
Journal article
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
DOI: 10.1200/JCO.20.005722020
Journal article
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
DOI: 10.1182/bloodadvances.20200028102020
Book Chapter
Granulocyte Colony-Stimulating Factor
DOI: 10.1201/9781003067405-112020
Journal article
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
DOI: 10.1182/blood.20200047822020
Journal article
Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.
DOI: 10.1200/jco.2020.38.15_suppl.8051